NEW YORK (GenomeWeb News) – Celltrion will evaluate Crucell’s cell lines for use in its drug development services programs under a new licensing agreement, Crucell said today.
The non-exclusive agreement allows Celltrion to evaluate Crucell’s STAR technology, which is used in producing recombinant human antibodies and proteins, for its drug programs, Crucell said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Associated Press reports that the US government wasted $341,000 on travel by former Health and Human Services Secretary Tom Price.

Women who post YouTube science videos get more critical comments and more comments about their appearance than male video hosts, the New York Times reports.

The Wall Street Journal writes that participating in genetic research brings up the specter of past research ethics lapses for some African Americans.

In PLOS this week: sequences influencing yeast prion aggregation or degradation, dengue virus genetic variants affect transmission dynamics, and more.